Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Clinical trial NCT05445765 · UNKNOWN

Trial details

NCT number: NCT05445765
Sponsor: iCell Gene Therapeutics
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed and/or Refractory Acute Myeloid Leukemia High Risk Hematologic Malignancies

Start date: 2022-07-01
Primary completion: 2024-06-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.